Randomized studies of growth factors as priming therapy for acute myeloid leukemia
. | . | . | . | . | . | Growth factor vs control group . | . | |
|---|---|---|---|---|---|---|---|---|
| Reference . | No. of patients . | Median age, y . | AML state . | Growth factor/control . | Day of first administration* . | % CR . | % overall survival . | |
| Ohno et al13 | 58 | 43-47 | Relapsed/refractory | Filgrastim/placebo | -2 | 50/37 | Same | |
| Estey et al14 | 197† | 58-61 | De novo/secondary | Filgrastim/control | -1 | 63/54 | Same | |
| Heil et al15 | 80 | 55 | De novo | Molgrastim/placebo | -2 | 81/79 | 45/49 (at 43 mo) | |
| Zittoun et al16 | 51 | 54 | Previously untreated | Molgrastim/control | -1 | 72/77 | Same | |
| Löwenberg et al17 | 318 | 68 | De novo/secondary | Molgrastim/control | -1 | 56/55 | 22/22 (at 24 mo) | |
| Witz et al18 | 240 | 66 | De novo | Molgrastim/placebo | +1 | 62/61 | 44/19 (at 24 mo)‡ | |
| Thomas et al19 | 192 | 46-47 | Relapsed/refractory | Molgrastim/placebo | -2 | 65/59 | Same | |
| Löwenberg et al20 | 640 | 44 | De novo/secondary | Lenograstim/control | -1 | 79/83 | 40/35 (at 48 mo)§ | |
| Rowe et al21 | 245 | 67-69 | Previously untreated | Sargramostim/placebo | -2 | 38/40 | Same | |
| Löfgren et al22 | 110 | 77 | De novo | Sargramostim/control | -1 | 65/64 | 8/10∥ (at 72 mo) | |
. | . | . | . | . | . | Growth factor vs control group . | . | |
|---|---|---|---|---|---|---|---|---|
| Reference . | No. of patients . | Median age, y . | AML state . | Growth factor/control . | Day of first administration* . | % CR . | % overall survival . | |
| Ohno et al13 | 58 | 43-47 | Relapsed/refractory | Filgrastim/placebo | -2 | 50/37 | Same | |
| Estey et al14 | 197† | 58-61 | De novo/secondary | Filgrastim/control | -1 | 63/54 | Same | |
| Heil et al15 | 80 | 55 | De novo | Molgrastim/placebo | -2 | 81/79 | 45/49 (at 43 mo) | |
| Zittoun et al16 | 51 | 54 | Previously untreated | Molgrastim/control | -1 | 72/77 | Same | |
| Löwenberg et al17 | 318 | 68 | De novo/secondary | Molgrastim/control | -1 | 56/55 | 22/22 (at 24 mo) | |
| Witz et al18 | 240 | 66 | De novo | Molgrastim/placebo | +1 | 62/61 | 44/19 (at 24 mo)‡ | |
| Thomas et al19 | 192 | 46-47 | Relapsed/refractory | Molgrastim/placebo | -2 | 65/59 | Same | |
| Löwenberg et al20 | 640 | 44 | De novo/secondary | Lenograstim/control | -1 | 79/83 | 40/35 (at 48 mo)§ | |
| Rowe et al21 | 245 | 67-69 | Previously untreated | Sargramostim/placebo | -2 | 38/40 | Same | |
| Löfgren et al22 | 110 | 77 | De novo | Sargramostim/control | -1 | 65/64 | 8/10∥ (at 72 mo) | |
Filgrastim indicates Escherichia coli—derived recombinant human granulocyte colony-stimulating factor; Lenograstim, Chinese hamster ovary—derived recombinant human G-CSF; Molgrastim, Escherichia coli—derived recombinant human GM-CSF; and Sargramostim, yeast-derived recombinant human granulocyte-macrophage colony-stimulating factor.
Day of first administration of the growth factor in relation to the start of chemotherapy.
Including 74 patients with myelodysplastic syndrome.
P = .003.
P = .16; DFS 45/33, P = .02.
P = .07.